Citadel Advisors
PDLI

Citadel Advisors’s PDL BioPharma, Inc. PDLI Stock Holding History

Citadel Advisors’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-11,100
Closed -$41K – 10373
2019
Q1 		$41K Sell
11,100
-3,700
-25% -$12.5K ﹤0.01% 8899
2018
Q4 		$43K Sell
14,800
-2,700
-15% -$7.42K ﹤0.01% 8529
2018
Q3 		$46K Buy
17,500
+4,100
+31% +$10.1K ﹤0.01% 8822
2018
Q2 		$31K Buy
13,400
+100
+0.8% +$279 ﹤0.01% 8559
2018
Q1 		$39K Buy
+13,300
New +$36.3K ﹤0.01% 7995
2017
Q4 		– Sell
-23,300
Closed -$79K – 8847
2017
Q3 		$79K Buy
23,300
+2,400
+11% +$6.67K ﹤0.01% 7095
2017
Q2 		$52K Sell
20,900
-8,200
-28% -$18.9K ﹤0.01% 7087
2017
Q1 		$66K Sell
29,100
-13,100
-31% -$29K ﹤0.01% 6980
2016
Q4 		$89K Buy
42,200
+3,800
+10% +$10.6K ﹤0.01% 6717
2016
Q3 		$129K Buy
38,400
+600
+2% +$1.91K ﹤0.01% 6550
2016
Q2 		$119K Buy
37,800
+8,100
+27% +$27K ﹤0.01% 6121
2016
Q1 		$99K Buy
29,700
+13,600
+84% +$42.4K ﹤0.01% 6035
2015
Q4 		$57K Buy
16,100
+4,900
+44% +$20.5K ﹤0.01% 7215
2015
Q3 		$56K Buy
11,200
+300
+3% +$1.72K ﹤0.01% 7507
2015
Q2 		$70K Sell
10,900
-4,100
-27% -$27.5K ﹤0.01% 7423
2015
Q1 		$106K Sell
15,000
-18,600
-55% -$135K ﹤0.01% 6807
2014
Q4 		$259K Buy
33,600
+7,400
+28% +$58.6K ﹤0.01% 5649
2014
Q3 		$196K Buy
26,200
+10,100
+63% +$93.8K ﹤0.01% 5750
2014
Q2 		$156K Buy
16,100
+5,100
+46% +$45.5K ﹤0.01% 5836
2014
Q1 		$91K Sell
11,000
-1,800
-14% -$15.4K ﹤0.01% 6292
2013
Q4 		$108K Buy
12,800
+1,100
+9% +$9.27K ﹤0.01% 5550
2013
Q3 		$93K Buy
11,700
+7,100
+154% +$57.1K ﹤0.01% 5401
2013
Q2 		$36K Buy
+4,600
New +$35.9K ﹤0.01% 5821

Other funds holding PDLI

SPC
Silver Point Capital Greenwich, Connecticut $1.3B AUM 18.3% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $39.9B AUM 29.7% 1-Year Est. Return
GCIA
Gabelli & Co Investment Advisers Rye, New York $674M AUM 64.52% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
GF
Gabelli Funds Rye, New York $14.8B AUM 32.24% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
WG
Winton Group London, United Kingdom $2.85B AUM 30.73% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

Citadel Advisors's PDLI Position: Q4 2020 in Review

Citadel Advisors sold out of PDL BioPharma, Inc. (PDLI) in Q4 2020, closing a stake of 1,957,423 shares — an estimated $6.17M sold.

Citadel Advisors first reported a position in PDLI in Q2 2013 and held it in 29 quarters. The position peaked at $12.4M in Q1 2017. 33 funds tracked by Wall St. Rank hold PDLI as of Q4 2020.

  • Citadel Advisors reported no remaining PDL BioPharma, Inc. position as of Q4 2020 after selling out during the quarter.
  • Citadel Advisors sold 1,957,423 PDL BioPharma, Inc. shares in Q4 2020, an estimated $6.17M.
  • Citadel Advisors first reported a position in PDL BioPharma, Inc. in Q2 2013 and held it in 29 quarters.
  • Citadel Advisors's PDL BioPharma, Inc. position peaked at $12.4M in Q1 2017.
  • 33 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2020.

Based on Citadel Advisors's 13F filing for Q4 2020, filed 16 Feb 2021.